Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent (Q39332214)

11 September 2017

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent (English)

1 reference

11 September 2017

Lorrene A Buckley

1

1 reference

11 September 2017

Atsushi Sanbuissho

2

1 reference

11 September 2017

James J Starling

3

1 reference

11 September 2017

Mary Pat Knadler

4

1 reference

11 September 2017

Philip W Iversen

5

1 reference

11 September 2017

Joseph A Jakubowski

6

1 reference

11 September 2017

12 June 2012

1 reference

International Journal of Toxicology

11 September 2017

1 reference

11 September 2017

31

1 reference

11 September 2017

4

1 reference

11 September 2017

317-325

1 reference

Weighing benefits and risks--the FDA's review of prasugrel

11 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Mode of action in relevance of rodent liver tumors to human cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Cancer among epileptic patients exposed to anticonvulsant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1091581812445073

21 January 2018

Identifiers

DOI

10.1177/1091581812445073

1 reference

11 September 2017

1 reference